Difference between revisions of "Tirabrutinib (Velexbru)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
||
| Line 8: | Line 8: | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2020-03-25: Newly indicated for the treatment of relapsed or refractory primary [[CNS lymphoma|central nervous system (CNS) lymphoma]]. | *2020-03-25: Newly indicated for the treatment of relapsed or refractory primary [[CNS lymphoma|central nervous system (CNS) lymphoma]]. | ||
| − | *2020-08-21: | + | *2020-08-21: New indications for the treatment of [[Waldenström macroglobulinemia|Waldenström's macroglobulinemia]] and lymphoplasmacytic lymphoma. |
==Also known as== | ==Also known as== | ||
Latest revision as of 02:00, 11 June 2023
Mechanism of action
BTK inhibitor
Diseases for which it is used
History of changes in PMDA indication
- 2020-03-25: Newly indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma.
- 2020-08-21: New indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.
Also known as
- Code name: GS-4059
- Brand name: Velexbru